Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Evidence of Brentuximab Vedotin Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant

NCT04776265 is registered in ClinicalTrials.gov with Grupo Argentino de Tratamiento de la Leucemia Aguda as lead sponsor.

NCT NCT04776265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Evidence of Brentuximab Vedotin Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant
Lead sponsor
Grupo Argentino de Tratamiento de la Leucemia Aguda
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2021
Completion date
April 1, 2024
Enrollment
100 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, adult, refractory hodgkin lymphoma, relapsed hodgkin's disease, adult